Motor system diseases (MSDs) are diseases that occur in bones, joints, muscles, ligaments, and other parts. Common MSDs include osteoarthritis (OA) and osteoporosis (OP). These diseases seriously affect people's normal life. Due to their excellent compatibility, good permeability, natural stability, low immunogenicity, and low toxicity, exosomes as a new drug delivery system have attracted the attention of many researchers in recent years. Numerous studies have shown that exosomes play an important role in bone metabolism. This intercellular communication through exosomes may become a therapeutic target for MSDs, providing new ideas for biomedical workers. To realize the treatment of MSDs by exosomes, it is crucial to select a suitable MSD animal model to study the efficacy and safety of exosome drugs. Creative Biolabs is a world-leading supplier that can provide one-stop exosome technology services, and can provide various MSD animal models for customers to choose from.
Fig.1 Mechanism diagram of platelet lysates-derived exosomes-alendronate preparation targeting bone.1,2
We can provide including but not limited to the following MSD animal models for exosome functional research.
MSD Animal Models | Method | Modeling Mechanism | Applicable Animals | Model Features |
---|---|---|---|---|
OA animal models | Anterior cruciate ligament transection surgery | After the anterior cruciate ligament is severed, knee extension and flexion to 90° can increase the forward displacement of the knee joint, and at the same time increase the inward rotation of the knee joint, which causes changes in the joint force and eventually causes OA. | Rat、rabbit | This method has the advantages of simple operation and small structural damage, and the resulting OA lesion progresses slowly, which is suitable for exosome drug research. |
Hulth's method | Resection of the anterior and posterior cruciate ligaments, medial collateral ligament, and medial meniscus can cause joint instability. After the operation, the injured limb is not fixed, which will increase the wear between the articular surfaces and promote the degeneration of the articular cartilage. | Rat、rabbit | The degree of OA in this model is severe, similar to the middle and late stages of human OA. | |
Meniscus tear surgery | The loss of the meniscus can increase the wear between joints and accelerate the degeneration of articular cartilage. | Rat、rabbit | This model exhibits progressive articular cartilage damage similar to human OA. | |
Adjuvant induction | The structure of MtbH37Ra located in Mycobacterium tuberculosis is similar to that of HSP650 on the joint synovium, and both can be recognized by the same T cell clone, thereby inducing an immune response against the joint. | Rat | This method is simple to operate, the onset is faster, and the performance is similar to that of rheumatoid OA. | |
Collagen induction | Heterogeneous type II collagen can induce an autoimmune response in vivo against type II collagen in articular cartilage. | Mouse, rat | The articular cartilage degeneration in this model is obvious and lasts for a long time. | |
OP animal models | Bilateral oophorectomy | After the bilateral ovaries were removed, the level of estrogen secretion in the animals decreased, which caused the activation of osteoclasts and the compensatory enhancement of osteoblasts. But the general trend is that bone resorption is greater than bone formation, and bone mass decreases. | Mouse, rat | The modeling factor is single. Moreover, the model has stable effects, good reproducibility, and high reliability of experimental results, which can well simulate the bone metabolism characteristics of postmenopausal OP. |
Glucocorticoid induction | Glucocorticoids can up-regulate RANKL and down-regulate OPG, thereby inhibiting osteoblast differentiation, promoting bone resorption, and ultimately leading to bone loss. | Rat | This model is the most common type of secondary OP and has a high success rate of modeling. |
Creative Biolabs provides services for the research and discovery phase of exosome drugs for the treatment of MSDs for global customers. If you have an idea for in vivo research of exosome drugs for the treatment of MSDs, please contact us. We will provide you with the most suitable MSD animal model according to your needs. In addition, we can construct therapeutic exosomes for you by providing exosome extraction services, exosome identification services, exosome engineering services, and by providing exosome labeling services, in vivo and in vitro exosome verification services to accelerate the further conversion of results.
References